ABSTRACT Angiotensin II elicits contractile responses in the coronary arteries and myocardial tissue, which suggests that blockade of the renin-angiotensin system by specific agents should lead to both coronary vasodilation and an alteration of left ventricular inotropism. The present work was designed to delineate -independently from its systemic effects -the intrinsic actions of an angiotensin converting-enzyme inhibitor on the coronary circulation and left ventricular function. To minimize peripheral effects, a bilateral intracoronary infusion of enalaprilat (0.05 mg.miW-1, 1 mlbmin71 in each coronary artery) was performed in 16 patients with dilated cardiomyopathy. All patients had normal coronary arteriograms. In 12 patients (group I) the intracoronary infusion of enalaprilat resulted in minimal peripheral changes, with a 5% reduction in the mean aortic pressure (p < .05) ically observed effects of converting-enzyme inhibitors could result from the marked systemic vasodilator actions of captopril22 and enalapril23 when they are administered by the oral or intravenous route. Indexes of left ventricular function and coronary blood flow are both highly sensitive to the loading conditions of the heart in the sense that a reduction in afterload may result by itself in an improvement in variables of left ventricular function and a reduction in coronary blood flow. 24
have been demonstrated in various species. 46 Inhibition of the renin-angiotensin system by specific agents is therefore expected to result in both negative inotropic effects and vasodilation of the coronary arteries. Instead, the majority of patients receiving captopril or enalapril exhibit an elevation of left ventricular ejection fraction and cardiac index.714 Similarly, most studies of coronary blood flow after angiotensin converting-enzyme inhibition have demonstrated either no change or a reduction of coronary flow, [15] [16] [17] [18] [19] [20] [21] suggesting that these drugs had little effect -if any -on the coronary vasculature. Such a discrepancy between the experimental properties of angiotensin II and the clin-337 ically observed effects of converting-enzyme inhibitors could result from the marked systemic vasodilator actions of captopril22 and enalapril23 when they are administered by the oral or intravenous route. Indexes of left ventricular function and coronary blood flow are both highly sensitive to the loading conditions of the heart in the sense that a reduction in afterload may result by itself in an improvement in variables of left ventricular function and a reduction in coronary blood flow. 24 To delineate the specific effects of a soluble solution of enalapril (enalaprilat, MK 422, Merck Sharp & Dohme -Chibret Laboratories) on both left ventricular performance and coronary circulation of patients with dilated cardiomyopathy, a bilateral intracoronary infusion technique was used, thereby minimizing the peripheral action of the drug. This approach allowed for a specific determination of the direct myocardial and coronary effects of enalaprilat, and avoided problems inherent in evaluating agents with both systemic and cardiac actions.
Methods
Patient selection. Sixteen patients -10 men and six women (mean age 50 + 10 years) -with dilated cardiomyopathy as documented by echocardiography and previous episodes of congestive heart failure were investigated. All these patients were in sinus rhythm and had angiographically normal coronary arteries, and no cause could be found for their ventricular dysfunction.
Catheterization procedure. Cardiac catheterization was performed after the patients gave informed consent; all cardiac drugs were discontinued 48 hr before the study, and all patients were in the fasting state for at least 12 hr before the procedure. No premedication was administered and local anesthesia was achieved with 1% lidocaine. In 12 patients (group I) a No. 7F high-fidelity double-tipped micromanometer catheter (PC-770, Millar Instruments) was placed into the left ventricle through a femoral artery and positioned to record left ventricular and aortic pressures simultaneously. Two No. SF sheaths were placed into the other femoral artery for left ventriculography and coronary arteriography catheters. A No. 7F Swan-Ganz thermodilution catheter (Edwards Laboratory) was placed into the pulmonary artery via a femoral vein for determination of cardiac output (Cardiac output computer 9520 A, Edwards Laboratory). A No.
7F coronary sinus thermodilution catheter (Wilson Webster Laboratories) was inserted into the left subclavian vein and positioned into the coronary sinus for measurement of coronary sinus blood flow; the position of the catheter was controlled by fluoroscopy before each measurement of coronary sinus blood flow to place the proximal thermistor in front of the posterior interventricular vein leading to the coronary sinus.
In four patients (group II) a different protocol without measurement of coronary sinus blood flow was followed.
Protocol. In group I patients, four periods (tl, t2, t3, and t4)
were observed for completion of the protocol ( figure 1 Hemodynamic data (table 1) . The comparison between data obtained at t2 and t3, i.e., before and during the intracoronary infusion of enalaprilat, indicated a moderate reduction in left ventricular systolic pressure (-5%, p < .05) and mean aortic pressure (-5%, p < .05). Cardiac index was reduced by 9% (p < .01) and the arteriovenous oxygen difference was enlarged (+9%, p < .01). There was no significant change in heart rate, left ventricular end-diastolic pressure, mean right atrial pressure, systemic vascular resistances, or rate-pressure product.
Coronary circulation (table 2) . In all patients, the intracoronary infusion of enalaprilat resulted in a significant elevation of coronary sinus blood flow between t2 and t3 (+ 19%, p < .001), with a parallel reduction in coronary resistance noted in 11 of 12 patients (-18%, p < .001). Coronary sinus oxygen content and pressure were significantly increased, while oxygen extraction by the myocardium was reduced. Myocardial oxygen consumption was unchanged.
Left ventricular performance ( 2, February 1988 slightly between the two left ventricular angiograms (+ 6%, p < .05). There was a significant reduction in left ventricular ejection fraction (-12%, p < .02) and left ventricular end-systolic wall stress/end-systolic volume ratio (-8%, p < .01) (figure 2). Left ventricular end-diastolic pressure, left ventricular systolic pressure, and left ventricular end-systolic wall stress were not significantly different in t1 and t4.
Group II patients. In group II patients, basal coronary arteriograms were normal and left ventricular angiographic data were not different from those in group I patients for left ventricular mass (94 ± 16 g_m-2), end-diastolic wall thickness (7.3 + 0.7 mm), enddiastolic volume (138 ± 24 mlm-2), ejection fraction (32 + 18%), end-systolic wall stress (370 ± 63 g cm-2), and end-systolic stress/end-systolic volume ratio (2.49 ± 0.66 g_cm-2_ml-1).
Serial data obtained in group II patients are presented in figure 3 . Bilateral intracoronary infusion of saline, the vehicle for enalaprilat, resulted in no significant hemodynamic or hormonal change (tl). At the end of the bilateral intracoronary infusion of enalaprilat, cardiac index was significantly reduced and arteriovenous oxygen difference was enlarged (t2); other hemodynamic variables remained stable. These modifications were not affected by the removal of the right coronary catheter (t3), but returned to basal values 10 min after discontinuation of the infusion of enalaprilat (t4). Intracoronary enalaprilat resulted in no significant variation in plasma renin activity or plasma aldosterone.
Discussion
In the present study we sought to determine effects of the bilateral intracoronary infusion of enalaprilat in patients with dilated cardiomyopathy. This intracoronary infusion resulted in both significant coronary vasodilation and a myocardial negative inotropic effect that could not be explained by peripheral changes. to an augmented cardiac index and ejection fraction. In addition, these unidirectional changes in favor of a depressant effect of enalaprilat on left ventricular function occurred without significant alteration of left ventricular preload, i.e., left ventricular end-diastolic pressure and volume. No significant variation in plasma renin activity or plasma aldosterone occurred after intracoronary enalaprilat in group II patients, providing an additional argument for the lack of systemic angiotensin converting-enzyme inhibition in this study. The modest decrease of left ventricular end-diastolic volume noted after intracoronary enalaprilat might have been produced by the resting position of the patients in the catheterisation laboratory. Although it cannot be ruled out, such an explanation is unlikely to TABLE 3 Left ventricular angiographic data before (tl) and during the intracoronary infusion of enalaprilat (t4) account for our results, since cardiac index and heart rate of group II patients measured at the end of the protocol after a 45 min period in the supine position were identical to those measured initially. The myocardial effects of this intracoronary infusion could have resulted in part from the vehicle used for enalaprilat, which was saline. However, this was probably not the case, since the intracoronary infusion of saline in group II patients resulted in no hemodynamic changes, whereas the intracoronary infusion of enalaprilat in the same patients produced significant variations in cardiac index and in arteriovenous oxygen difference. These In contrast to previous data obtained after oral or intravenous administration of angiotensin converting-enzyme inhibitors, the intracoronary infusion of enalaprilat given in our study resulted in a marked elevation in coronary sinus blood flow, paralleled by a similar reduction in coronary resistance. Difficulties in demonstrating the coronary vasodilator effects of captopril or teprotide can probably be explained by the simultaneous reductions in systemic resistances and myocardial oxygen consumption that are usually noted after oral or intravenous administration of these drugs. Since coronary blood flow is closely linked to the myocardial metabolic demand, a reduction in myocardial oxygen consumption will be followed by an appropriate decrease in coronary flow. 24 No significant change in the major determinants of the myocardial metabolic demand were noted in this study: the endsystolic stress, rate-pressure product, and myocardial oxygen consumption remained stable throughout. The significant elevation of the oxygen content and pressure in the coronary sinus blood -together with a reduced coronary sinus oxygen extraction -further support a direct action of enalaprilat on the coronary vasculature. Another difference between this study and previous reports of angiotensin converting-enzyme inhibitors and coronary blood flow is that in a substantial proportion of patients who were studied after captopril, enalapril, or teprotide, heart failure was the result of coronary artery disease: the absence of an elevation in coronary blood flow in these patients with advanced ischemic cardiomyopathy could reflect a limited coronary reserve, with proximal atherosclerotic stenosis restraining an elevation of coronary blood flow.44 Our current assessment of the coronary vasodilator action CIRCULATION of enalaprilat in human heart failure is in agreement with early experimental observations by Cohen et al. ,' who found that angiotensin injected directly into the coronary artery of anesthetized dogs increased coronary resistance, and with both initial46 and recent47 experimental reports demonstrating coronary vasodilation in dogs after blockade of the renin-angiotensin system by teprotide or enalapril.
In summary, specific effects of angiotensin converting-enzyme inhibitors on myocardial contractility and coronary circulation are masked when these drugs are administered orally or intravenously because of the reduction in ventricular loading. Indeed, useful information regarding the myocardial and coronary effects are provided when these drugs are administered by the intracoronary route. The present study demonstrates that a bilateral intracoronary infusion of enalaprilat results in both a negative inotropic effect on the left ventricle and selective vasodilation of the coronary arteries in patients with dilated cardiomyopathy.
